CoChat
Sign Up
Cited by 126Schizophrenia research and treatmentPharmacogenetics and Drug MetabolismHistorical Psychiatry and Medical Practices

The DOI matches its Crossref record; 88 of the 90 references it cites were found in a registry or an index.

Clinical Pharmacokinetics of the Depot Antipsychotics

Jann, Michael W., Ereshefsky, Larry, Saklad, Stephen R.·1985·Clinical Pharmacokinetics
DOI 10.2165/00003088-198510040-00003
Open this paper in CoChat — free account

Abstract

The clinical pharmacokinetics of the 4 depot antipsychotics for which plasma level studies are available (i.e. fluphenazine enanthate and decanoate, haloperidol decanoate, clopenthixol decanoate and flupenthixol decanoate) are reviewed. The proper study of these agents has been handicapped until recently by the necessity of accurately measuring subnanomolar concentrations in plasma. Their kinetic properties, the relationship of plasma concentrations to clinical effects, and conversion from oral to injectable therapy are discussed. The depot antipsychotics are synthesised by esterification of the active drug to a long chain fatty acid and the resultant compound is then dissolved in a vegetable oil. The absorption rate constant is slower than the elimination rate constant and therefore, the depot antipsychotics exhibit 'flip-flop' kinetics where the time to steady-state is a function of the absorption rate, and the concentration at steady-state is a function of the elimination rate. Fluphenazine is available as both an enanthate and decanoate ester (both dissolved in sesame oil), although the decanoate is more commonly used clinically. The enanthate produces peak plasma concentrations on days 2 to 3 and declines with an apparent elimination half-life (i.e. the half-time of the apparent first-order decline of plasma concentrations) of 3.5 to 4 days after a single injection. The decanoate produces an early high peak which occurs during the first day and then declines with an apparent half-life ranging from 6.8 to 9.6 days following a single injection. After multiple injections of fluphenazine decanoate, however, the mean apparent half-life increases to 14.3 days, and the time to reach steady-state is 4 to 6 weeks. Withdrawal studies with fluphenazine decanoate suggest that relapsing patients have a more rapid plasma concentration decline than non-relapsing patients, and that the plasma concentrations do not decline smoothly but may exhibit 'lumps' due to residual release from previous injection sites or multicompartment redistribution. Cigarette smoking has been found to be associated with a 2.33-fold increase in the clearance of fluphenazine decanoate. In 3 different studies, fluphenazine has been proposed to have a therapeutic range from less than 0.15 to 0.5 ng/ml with an upper therapeutic range of 4.0 ng/ml. Plasma concentrations following the decanoate injection are generally lower than, but clinically equivalent to, those attained with the oral form of the drug. Haloperidol decanoate plasma concentrations peak on the seventh day following injection although, in some patients, this peak may occur on the first day.(ABSTRACT TRUNCATED AT 400 WORDS)

Overview

Integrity signals

Registry

Crossref · 10.2165/00003088-198510040-00003

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 90 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Jann, M. W., Ereshefsky, L., & Saklad, S. R.
Affiliations
The University of Texas at San Antonio Health Science Center (US)
ORCID
Venue
Clinical Pharmacokinetics
Publisher
Springer Science and Business Media LLC
Published
1985
Volume
10
Issue
4
Pages
315-333
ISSN
0312-5963 (ISSN-L)
DOI
10.2165/00003088-198510040-00003
OpenAlex
W2006123146
Cited by
125
References
90
Citations by year
2025: 5 · 2023: 1 · 2022: 1 · 2021: 10 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 6 · 2016: 4 · 2015: 3 · 2014: 3 · 2013: 4 · 2012: 5
FWCI
3.38
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Pharmacokinetics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Social Sciences › Psychology › Clinical Psychology › Historical Psychiatry and Medical Practices
Keywords
long-acting injectable antipsychotics, fluphenazine decanoate, fluphenazine enanthate, haloperidol decanoate, clopenthixol, flip-flop kinetics, plasma concentration-time curve, elimination half-life, therapeutic window, relapse
MeSH terms
Aging, Chemistry, Clopenthixol, Delayed-Action Preparations, Flupenthixol, Fluphenazine, Half-Life, Haloperidol, Humans, Kidney Diseases, Kinetics, Liver Diseases, Prolactin, Smoking, Antipsychotic Agents, Chemical Phenomena

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review